Skip to main content

Advertisement

SpringerLink
Log in

Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

In December 2021, long-acting injectable pre-exposure prophylaxis (LAI-PrEP) was approved for the prevention of HIV in at-risk adults and adolescents. LAI-PrEP may address adherence issues of daily oral daily PrEP and PrEP stigma. However, studies assessing LAI-PrEP willingness among PrEP naive Black and Hispanic sexual and gender minority (SGM) persons– a group disproportionately impacted by the HIV epidemic in the United States – is rare. To assess the extent of and characteristics of willingness to use LAI-PrEP in a national sample of Black and Hispanic SGM who are self-reported that they have never used PrEP. We analyzed data from a national sample of Black and Hispanic SGM collected between March and August 2020. We used log-binomial regression models to assess characteristics associated with willingness to use LAI-PrEP. Of the overall sample (N = 380), the mean age was 24 (SD = 2.8) and the majority of the sample (54%, n = 205) reported willingness to use LAI-PrEP. In multivariable log-binomial regression models, PrEP stigma was independently associated with less [prevalence ratio (PR) = 0.7, 95% confidence interval (CI) = 0.6, 0.9], while number of sexual partners in the past 12 months was associated with a more willingness to use LAI-PrEP (PR = 1.1, 95% CI = 1.0, 1.2). Our findings highlight the persistence of PrEP stigma as a potential barrier to willingness to use LAI-PrEP in this sample of Black and Hispanic SGM who have never used PrEP. Additional work needs to be done to reduce PrEP stigma more broadly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

Data is available upon reasonable request.

Code Availability

Not applicable.

References

  1. CDC. Centers for Disease Control and Prevention. HIV Surveillance Data Tables (early release): Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses and linkage to HIV medical care [Internet]. 2019 [cited 2022 Feb 5]. Available from: https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-2/cdc-hiv-surveillance-tables-vol-1-no-2.pdf.

  2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hare CB, Coll J, Ruane P, Molina JM, Mayer KH, Jessen H et al. The Phase 3 Discover Study: Daily F/ TAF or F/TDF for HIV Preexposure Prophylaxis. In Seattle, WA; 2019.

  4. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand preexposure Prophylaxis in men at High Risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.

    Article  CAS  PubMed  Google Scholar 

  5. Morgan E, Eaton LA, Watson RJ. Cannabis Use Frequency is Associated with PrEP Cessation and Self-reported HIV Diagnosis. AIDS Behav [Internet]. 2023 Jul 8 [cited 2023 Sep 12]; https://doi.org/10.1007/s10461-023-04117-w.

  6. Okafor CN, Hucks-Ortiz C, Hightow-Weidman LB, Magnus M, Emel L, Beauchamp G, et al. Associations between Self-reported Substance Use behaviors and PrEP Acceptance and Adherence among Black MSM in the HPTN 073 study. J Acquir Immune Defic Syndr. 2020;85(1):23–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Serota DP, Rosenberg ES, Sullivan PS, Thorne AL, Rolle CPM, Del Rio C, et al. Pre-exposure Prophylaxis Uptake and Discontinuation among Young Black men who have sex with men in Atlanta, Georgia: a prospective cohort study. Clin Infect Dis. 2020;71(3):574–82.

    Article  PubMed  Google Scholar 

  8. Sidebottom D, Ekström AM, Strömdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence? BMC Infect Dis [Internet]. 2018 Nov 16 [cited 2019 Jul 5];18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240194/.

  9. Van Gerwen OT, Yigit I, Crockett KB, Turan B. The Relationship between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence among current HIV pre-exposure Prophylaxis users in the Southeastern U.S. AIDS Behav. 2023;27(5):1478–85.

    Article  PubMed  Google Scholar 

  10. Wade Taylor S, Mayer KH, Elsesser SM, Mimiaga MJ, O’Cleirigh C, Safren SA. Optimizing content for pre-exposure Prophylaxis (PrEP) counseling for men who have sex with men: perspectives of PrEP users and high-risk PrEP Naïve men. AIDS Behav. 2014;18(5):871–9.

    Article  CAS  PubMed  Google Scholar 

  11. Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–7.

    Article  PubMed  PubMed Central  Google Scholar 

  12. FDA. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention [Internet]. 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention2/5/2022.

  13. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender men and Transgender women. N Engl J Med. 2021;385(7):595–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Golub SA, Meyers K, Enemchukwu C, Perspectives, Lesbian RF. Gay, bisexual, Transgender, and Queer/Questioning Youth of Color regarding Engagement in Biomedical HIV Prevention. J Adolesc Health. 2020;66(3):281–7.

    Article  PubMed  Google Scholar 

  15. John SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C. Will gay and bisexual men taking oral pre-exposure prophylaxis (PrEP) switch to long-acting injectable PrEP should it become available? AIDS Behav. 2018;22(4):1184–9.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Levy ME, Agopian A, Magnus M, Rawls A, Opoku J, Kharfen M, et al. Is long-acting Injectable Cabotegravir likely to Expand PrEP Coverage among MSM in the District of Columbia? J Acquir Immune Defic Syndr. 2021;86(3):e80–2.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, et al. Acceptability of long-acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected individuals: HPTN 077. AIDS Behav. 2020;24(9):2520–31.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, et al. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: patient perspectives from the ECLAIR trial. HIV Clin Trial. 2018;19(4):129–38.

    Article  CAS  Google Scholar 

  19. Hall EW, Heneine W, Sanchez T, Sineath RC, Sullivan P. Preexposure Prophylaxis Modality preferences among men who have sex with men and Use Social Media in the United States. J Med Internet Res. 2016;18(5):e111.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Parsons JT, Rendina HJ, Whitfield THF, Grov C. Familiarity with and preferences for oral and long-acting Injectable HIV pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual men in the U.S. AIDS Behav. 2016;20(7):1390–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Greene GJ, Swann G, Fought AJ, Carballo-Diéguez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure Prophylaxis (PrEP), daily oral PrEP, or condoms for HIV Prevention among U.S. men who have sex with men. AIDS Behav. 2017;21(5):1336–49.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Schoenberg P, Edwards OW, Merrill L, Martinez CA, Stephenson R, Sullivan PS, et al. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study. J Int AIDS Soc. 2023;26(3):e26077.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Morgan E, Caba AE, Eaton LA, Watson RJ. PrEP Access affected by COVID-19 is Associated with increased odds of HIV Seroconversion. JAIDS J Acquir Immune Defic Syndr. 2022;91(2):138.

    Article  CAS  PubMed  Google Scholar 

  25. Watson RJ, Morgan E, Collibee C, Kalinowski J, Cunningham C, Edelman EJ, et al. Substance use and Healthcare utilization across the Pre-exposure Prophylaxis (PrEP) Care Cascade among black and latino men who have sex with men. Subst Use Misuse. 2022;57(11):1698–707.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Higgins-Biddle JC, Babor TF. A review of the Alcohol Use disorders Identification Test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: past issues and future directions. Am J Drug Alcohol Abuse. 2018;44(6):578–86.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bogart LM, Thorburn S. Are HIV/AIDS conspiracy beliefs a barrier to HIV prevention among African americans? J Acquir Immune Defic Syndr. 2005;38(2):213–8.

    Article  PubMed  Google Scholar 

  28. Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and conspiracy beliefs related to pre-exposure Prophylaxis (PrEP) and interest in using PrEP among Black and White men and Transgender women who have sex with men. AIDS Behav. 2017;21(5):1236–46.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Meyer IH. Minority Stress and Mental Health in Gay men. J Health Soc Behav. 1995;36(1):38–56.

    Article  CAS  PubMed  Google Scholar 

  30. Blizzard L, Hosmer DW. Parameter estimation and goodness-of-fit in log binomial regression. Biom J. 2006;48(1):5–22.

    Article  CAS  PubMed  Google Scholar 

  31. Calder BJ, Schieffer RJ, Bryndza Tfaily E, D’Aquila R, Greene GJ, Carballo-Diéguez A, et al. Qualitative Consumer Research on Acceptance of Long-Acting Pre-exposure Prophylaxis products among men having sex with men and Medical Practitioners in the United States. AIDS Res Hum Retroviruses. 2018;34(10):849–56.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Miller AS, Krakower DS, Mayer KH. The potential of Long-Acting, Injectable PrEP, and impediments to its Uptake. J Urban Health. 2023;100(1):212–4.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Biello KB, Oldenburg CE, Mitty JA, Closson EF, Mayer KH, Safren SA, et al. The safe sex conundrum: anticipated stigma from sexual partners as a barrier to PrEP Use among Substance using MSM engaging in transactional sex. AIDS Behav. 2017;21(1):300–6.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Freeborn K, Portillo CJ. Does pre-exposure prophylaxis (PrEP) for HIV prevention in men who have sex with men (MSM) change risk behavior? A systematic review. J Clin Nurs. 2018;27(17–18):3254–65.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Grov C, Westmoreland DA, D’Angelo AB, Pantalone DW. How has HIV Pre-exposure Prophylaxis (PrEP) changed sex? A Review of Research in a New Era of Bio-behavioral HIV Prevention. J Sex Res. 2021;58(7):891–913.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, et al. Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus infection on sexual risk behavior in men who have sex with men: a systematic review and Meta-analysis. Clin Infect Dis. 2018;67(5):676–86.

    Article  PubMed  Google Scholar 

  37. USPHS. Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. [Internet]. 2021 [cited 2023 Sep 11]. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf.

  38. Carneiro PB, Westmoreland DA, Patel VV, Grov C. Factors associated with being PrEP-naïve among a US national cohort of former and naïve PrEP participants meeting objective criteria for PrEP care. Arch Sex Behav. 2021;50(4):1793–803.

    Article  PubMed  Google Scholar 

  39. Curley CM, Rosen AO, Mistler CB, Eaton LA. Pleasure and PrEP: a systematic review of studies examining pleasure, sexual satisfaction, and PrEP. J Sex Res. 2022;59(7):848–61.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Dibble KE, Murray SM, Wiginton JM, Maksut JL, Lyons CE, Aggarwal R, et al. Associations between HIV testing and multilevel stigmas among gay men and other men who have sex with men in nine urban centers across the United States. BMC Health Serv Res. 2022;22(1):1179.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Oldenburg CE, Perez-Brumer AG, Hatzenbuehler ML, Krakower D, Novak DS, Mimiaga MJ, et al. State-level structural sexual stigma and HIV prevention in a national online sample of HIV-uninfected men who have sex with men in the United States. AIDS. 2015;29(7):837–45.

    Article  PubMed  Google Scholar 

  42. Quinn K, Dickson-Gomez J, Zarwell M, Pearson B, Lewis M. A Gay Man and a doctor are just like, a recipe for Destruction: how racism and homonegativity in Healthcare Settings Influence PrEP Uptake among Young Black MSM. AIDS Behav. 2019;23(7):1951–63.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Behler RL, Cornwell BT, Schneider JA. Patterns of Social Affiliations and Healthcare Engagement among Young, Black, Men who have sex with men. AIDS Behav. 2018;22(3):806–18.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

National Institute on Drug Abuse (K01DA047912; Okafor & K01DA047918; Watson).

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, Long School of Medicine, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas, 78229-3900, USA

    Chukwuemeka N. Okafor

  2. Department of Human Development and Family Sciences, University of Connecticut, Storrs, CT, USA

    Lisa Eaton & Ryan Watson

Authors
  1. Chukwuemeka N. Okafor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Eaton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryan Watson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chukwuemeka N. Okafor.

Ethics declarations

Ethical Approval

Study procedures were approved by the Institutional Review Boards at University of Connecticut.

Consent to Participate

Eligible participants provide consent to participate.

Consent for Publication

All authors consent to publishing the manuscript.

Conflict of Interest

None of the authors have any conflicts of interest to report.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okafor, C.N., Eaton, L. & Watson, R. Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons. AIDS Behav (2024). https://doi.org/10.1007/s10461-024-04314-1

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10461-024-04314-1

Keywords

Search

Navigation